postMONARCH: A phase 3 study of abemaciclib plus fulvestrant versus placebo plus fulvestrant in patients with HR+, HER2-, metastatic breast cancer following progression on a CDK4 & 6 inhibitor and endocrine therapy.

Authors

Kevin Kalinsky

Emory University at Winship Cancer Institute, Atlanta, GA

Kevin Kalinsky , Rachel M. Layman , Peter A. Kaufman , Stephanie L. Graff , Giampaolo Bianchini , Miguel Martin , Yanhong Zhou , Holly Knoderer , Lacey Litchfield , Seth Andrew Wander

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

LEONARDA-1: Phase III randomized study of lerociclib plus fulvestrant in patients with HR+, HER2- locally advanced or metastatic breast cancer that has progressed on prior endocrine therapy.

First Author: Binghe Xu

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

Phase 3 ENABLAR-2 study to evaluate enobosarm and abemaciclib combination compared to estrogen-blocking agent for the second-line treatment of AR+, ER+, HER2- metastatic breast cancer in patients who previously received palbociclib and estrogen-blocking agent combination therapy.

First Author: Elgene Lim

insert_chart_outlined

Poster

2015 ASCO Annual Meeting

bookmark_border

A phase Ib study of abemaciclib with therapies for metastatic breast cancer.

First Author: Sara M. Tolaney

insert_chart_outlined

Poster

2020 ASCO Virtual Scientific Program

bookmark_border

Phase II trial of SAR439859 vs endocrine monotherapy in pre- and post-menopausal, estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), locally advanced or metastatic breast cancer (BC) with prior exposure to hormonal therapies.

First Author: Sara M. Tolaney